What Is BPC-157? The Science Behind the Body Protection Compound

BPC-157 is a synthetic peptide composed of 15 amino acids, derived from a protein naturally present in human gastric juice. Its full name — Body Protection Compound-157 — reflects the protective function it was first identified for: maintaining and repairing the stomach lining.

Since its discovery in 1993, BPC-157 has become one of the most extensively studied peptides in preclinical research, with over 100 published studies demonstrating tissue repair, anti-inflammatory activity, and protective effects across nearly every organ system in the body.

Here's what you need to know about this compound, how it works, and what the science actually supports.

---

The Basics: BPC-157 at a Glance

BPC-157 is a pentadecapeptide — a chain of 15 amino acids with the specific sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It was first isolated and described by Dr. Predrag Sikirić and his research team at the University of Zagreb, Croatia.

What sets BPC-157 apart from most other peptides is a simple but significant property: it is stable in human gastric juice. Most peptides break down rapidly in the acidic environment of the stomach, which is why many require injection to be effective. BPC-157 doesn't. It survives gastric acid, which means it can be taken orally — a meaningful practical advantage.

The peptide occurs naturally in the body as part of a larger protein found in gastric secretions. Its native role is cytoprotection — protecting cells, particularly in the gastrointestinal lining, from damage. But research over the past three decades has revealed that its protective and repair-promoting effects extend far beyond the gut.

---

How Does BPC-157 Work?

BPC-157 doesn't operate through a single mechanism. Researchers describe it as "pleiotropic," meaning it influences multiple biological pathways simultaneously. This is part of what makes it unusual — and part of why it has such a broad range of studied applications.

It Promotes New Blood Vessel Growth

One of BPC-157's best-documented effects is angiogenesis — the formation of new blood vessels. It activates a receptor called VEGFR2 (vascular endothelial growth factor receptor 2) and stimulates nitric oxide production through the Akt-eNOS signaling pathway.

In practical terms: more blood vessels mean better delivery of oxygen and nutrients to damaged tissue. This mechanism underpins many of BPC-157's repair-related effects, from wound healing to tendon recovery.

A 2020 study in Scientific Reports confirmed that BPC-157 directly promotes VEGFR2 expression and angiogenesis in tissue with restricted blood flow, establishing a clear molecular basis for these effects.

It Modulates Inflammation

Chronic inflammation drives most forms of tissue damage. BPC-157 reduces pro-inflammatory cytokines while supporting the resolution phase of inflammation — the stage where the body shifts from damage response to actual repair.

This anti-inflammatory activity has been demonstrated in preclinical models of inflammatory bowel disease, NSAID-induced gut damage, arthritis, and traumatic injury.

It Supports Growth Factor Signaling

BPC-157 enhances the expression of growth hormone receptors in tendon fibroblasts and upregulates growth factors involved in tissue repair. A 2018 study in Molecules showed that BPC-157 increased JAK2 phosphorylation — a key downstream signaling pathway — providing a mechanism for its tendon and ligament healing properties.

It Interacts With the Nitric Oxide System

The nitric oxide (NO) system regulates blood vessel function, inflammation, and repair. BPC-157 disrupts the Caveolin-1/eNOS inhibitory complex, promoting nitric oxide production in a dose-dependent manner. This explains its broad vascular protective effects, including prevention of blood clots and maintenance of healthy blood flow in injured tissue.

For a deeper look at how peptides influence cellular communication, see our article on how peptides support cellular signaling.

---

What Has BPC-157 Been Studied For?

The research base for BPC-157 is extensive in preclinical models. Here are the primary areas of investigation.

Gut Health and GI Protection

As a peptide native to gastric juice, BPC-157's strongest evidence is in gastrointestinal applications:

• Inflammatory bowel disease: Reduced inflammation and promoted mucosal healing in colitis models, comparable to standard anti-inflammatory treatments
• NSAID-induced gut damage: Counteracted the gastrointestinal toxicity of common pain medications like ibuprofen — a significant clinical problem affecting millions of users
• Gastric ulcer healing: Accelerated ulcer repair through cytoprotective mechanisms
• Intestinal barrier function: Supported the integrity of the gut lining, which is relevant to "leaky gut" concerns

Musculoskeletal Repair

A 2025 systematic review covering 36 studies found that BPC-157 consistently improved healing outcomes across multiple tissue types:

• Tendons: Accelerated repair of transected Achilles tendons and rotator cuff injuries, with improved collagen organization
• Bones: Enhanced fracture healing with increased callus formation
• Muscles: Promoted regeneration of crushed and lacerated muscle tissue with reduced scarring
• Ligaments: Improved healing of medial collateral ligament injuries

The review's authors noted a "favorable preclinical safety profile" with no reported adverse effects across all 35 preclinical studies examined.

Neuroprotection

BPC-157's effects on the nervous system represent an active research area. Preclinical studies show:

• Protection against brain damage from traumatic injury
• Counteraction of neurotoxicity in dopaminergic systems
• Modulation of serotonin and dopamine pathways
• Protection against peripheral nerve damage

These effects appear to operate through the brain-gut axis — the communication network between the gastrointestinal system and the central nervous system.

Organ Protection

Preclinical models demonstrate cytoprotective effects in the liver (protection against alcohol and toxin damage), pancreas, and cardiovascular system.

---

What About Human Evidence?

This is an important question, and transparency matters.

As of early 2026, no large-scale human clinical trials for BPC-157 have been completed and published. The vast majority of evidence is preclinical — conducted in animal models, primarily rodents.

However, two developments are worth noting:

1. A 2025 pilot study by Lee and Burgess administered intravenous BPC-157 infusions (up to 20 mg) to two healthy adults. The compound was well tolerated with no adverse events or meaningful changes in cardiac, hepatic, renal, thyroid, or metabolic biomarkers. This represents the first published human safety data for IV BPC-157.

1. Phase II trial data in ulcerative colitis exists but has never been published in full detail in peer-reviewed journals, which remains a gap in the evidence base.

The consistency of preclinical results — beneficial effects with no reported toxicity across hundreds of studies — is unusual and has driven significant interest in clinical translation. But the absence of completed human trials is a limitation any informed consumer should understand.

For more on the regulatory landscape, read our guide on whether peptide supplements are legal in the US.

---

Is BPC-157 Safe?

Preclinical Safety Data

BPC-157 has one of the most favorable preclinical safety profiles of any studied peptide:

• No identified toxic or lethal dose threshold — no deaths observed even at doses of 20 mg/kg in rats
• No teratogenic effects (no birth defect potential observed)
• No genotoxic effects (no DNA damage)
• No anaphylactic effects (no severe allergic reactions)

Reported Side Effects

Based on the limited human data and practitioner reports, the most commonly reported effects include mild nausea, temporary fatigue, or headache — typically at higher doses and early in use.

Important Notes

• BPC-157 is prohibited in competitive sports by WADA and USADA under category S0 (non-approved substances)
• Product quality varies significantly between suppliers — look for third-party testing and certificates of analysis
• Individuals with conditions affected by angiogenesis should consult a healthcare provider before use

---

Oral vs. Injectable: Why It Matters

Many peptides must be injected because stomach acid destroys them. BPC-157 is different — its stability in gastric juice means oral supplementation is viable.

For gut-specific applications (IBD support, NSAID damage, general GI health), the oral route has strong preclinical support. The peptide interacts directly with the gastrointestinal lining during absorption.

For systemic applications (musculoskeletal repair, organ protection), both oral and injectable routes have shown efficacy in research models, though injectable forms deliver higher systemic bioavailability.

This gastric stability is what makes BPC-157 practical as an oral supplement — and it's one of the reasons it has gained traction in the wellness space while many other peptides remain injection-only.

To understand how delivery method affects peptide efficacy more broadly, see our comparison of injectable vs. oral peptides.

---

How BPC-157 Fits Into the Bioregulator Category

BPC-157 is classified as a bioregulatory peptide — a compound that influences cellular function by modulating gene expression and signaling pathways rather than simply providing nutritional building blocks. This distinguishes it from traditional supplements like protein powders or vitamin complexes.

Bioregulators work upstream. Instead of supplying raw materials, they deliver molecular instructions that influence how cells read and respond to their environment. BPC-157's multi-pathway mechanism — angiogenesis, inflammation modulation, growth factor signaling, and nitric oxide regulation — is a textbook example of this bioregulatory function.

If you're new to this category, our complete guide to bioregulators explains the broader science and how these compounds differ from conventional supplements.

---

Frequently Asked Questions

What does BPC-157 stand for?

BPC-157 stands for Body Protection Compound-157. The name reflects its native function — protecting cells in the gastrointestinal tract — and the "157" designates this specific 15-amino-acid sequence isolated from the larger BPC protein.

Is BPC-157 natural?

BPC-157 is derived from a protein that occurs naturally in human gastric juice. The supplement form is synthetic — manufactured to replicate the exact amino acid sequence found in the body. It is not extracted from animal or plant sources.

Can I take BPC-157 orally?

Yes. Unlike most peptides, BPC-157 is stable in gastric acid, making oral supplementation viable. This is one of its distinguishing properties and has been confirmed in multiple preclinical studies.

How long does it take for BPC-157 to work?

In preclinical research, measurable tissue repair effects appear within days of administration, with significant differences observed at 7-14 days. Individual timelines vary based on the application and personal physiology.

Does BPC-157 require a prescription?

When sold as an oral dietary supplement, BPC-157 does not require a prescription in the United States. It is not FDA-approved as a drug, meaning manufacturers cannot make disease treatment claims. Injectable forms may be subject to different regulations depending on state laws.

Can BPC-157 be combined with other peptides?

BPC-157 has complementary mechanisms to other bioregulatory peptides. It is commonly used alongside KPV for gut and inflammation support, and alongside Epitalon for broader cellular optimization. Specific combination protocols should be discussed with a healthcare provider.

---

The Bottom Line

BPC-157 is a naturally derived peptide with an unusually broad and consistent preclinical evidence base. Over three decades of research suggest it supports tissue repair, gut health, inflammation modulation, and organ protection through multiple biological pathways.

Its gastric stability makes it uniquely suited to oral supplementation — a practical advantage over most peptides in the market. The primary limitation is the gap between extensive preclinical promise and limited human clinical data, a reality that should inform expectations.

For those looking to support their body's repair and recovery systems with a well-researched bioregulatory peptide, BPC-157 represents one of the strongest evidence bases available.

Haven Wellness offers pharmaceutical-grade BPC-157 manufactured in GMP-certified facilities with third-party testing and full COA transparency.

---

This article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any new supplement regimen.

References:

• Sikirić P, et al. "Stable Gastric Pentadecapeptide BPC 157 and Wound Healing." Frontiers in Pharmacology, 2021.
• Gwyer D, Wragg NM, Wilson SL. "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing." Cell and Tissue Research, 2019.
• Chang CH, et al. "Modulatory effects of BPC 157 on vasomotor tone." Scientific Reports, 2020.
• Vukojevic J, et al. "BPC 157 Enhances Growth Hormone Receptor Expression in Tendon Fibroblasts." Molecules, 2018.
• Vasireddi N, et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." Orthopaedic Journal of Sports Medicine, 2025.
• Lee, Burgess. "Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study." 2025.
• Kang EA, et al. "BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection." Gut and Liver, 2019.
• "Multifunctionality and Possible Medical Application of the BPC 157 Peptide." Pharmaceuticals, 2025.